DE2251379A1 - Angstunterdrueckende arzneipraeparate - Google Patents
Angstunterdrueckende arzneipraeparateInfo
- Publication number
- DE2251379A1 DE2251379A1 DE2251379A DE2251379A DE2251379A1 DE 2251379 A1 DE2251379 A1 DE 2251379A1 DE 2251379 A DE2251379 A DE 2251379A DE 2251379 A DE2251379 A DE 2251379A DE 2251379 A1 DE2251379 A1 DE 2251379A1
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- phenyl
- radical
- hydrogen atom
- lower alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title description 11
- 230000001718 repressive effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- QUYPSOKUBYENRV-UHFFFAOYSA-N 1h-pyrazole;pyridine Chemical class C=1C=NNC=1.C1=CC=NC=C1 QUYPSOKUBYENRV-UHFFFAOYSA-N 0.000 claims description 8
- -1 Pfcenyl Chemical group 0.000 claims description 8
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000001589 carboacyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000005059 halophenyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000006501 nitrophenyl group Chemical group 0.000 claims 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 20
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 18
- 229960004782 chlordiazepoxide Drugs 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229960000278 theophylline Drugs 0.000 description 12
- 230000035939 shock Effects 0.000 description 11
- 230000035622 drinking Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000049 anti-anxiety effect Effects 0.000 description 8
- 208000019901 Anxiety disease Diseases 0.000 description 7
- 230000001624 sedative effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000004494 ethyl ester group Chemical group 0.000 description 4
- 229940126601 medicinal product Drugs 0.000 description 4
- 239000000932 sedative agent Substances 0.000 description 4
- 230000002557 soporific effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229940125713 antianxiety drug Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YGHYNWVXNWNXML-UHFFFAOYSA-N 1-ethyl-N-(propan-2-ylideneamino)pyrazol-4-amine Chemical compound C(C)N1N=CC(=C1)NN=C(C)C YGHYNWVXNWNXML-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- BUCORZSTKDOEKQ-UHFFFAOYSA-N 7-chloro-4-hydroxy-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-imine Chemical compound C=12C=C(Cl)C=CC2=NC(=NC)CN(O)C=1C1=CC=CC=C1 BUCORZSTKDOEKQ-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19069171A | 1971-10-19 | 1971-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2251379A1 true DE2251379A1 (de) | 1973-04-26 |
Family
ID=22702367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2251379A Pending DE2251379A1 (de) | 1971-10-19 | 1972-10-19 | Angstunterdrueckende arzneipraeparate |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US3784688A (enExample) |
| DE (1) | DE2251379A1 (enExample) |
| FR (1) | FR2157892B1 (enExample) |
-
1971
- 1971-10-19 US US00190691A patent/US3784688A/en not_active Expired - Lifetime
-
1972
- 1972-10-19 DE DE2251379A patent/DE2251379A1/de active Pending
- 1972-10-19 FR FR7237156A patent/FR2157892B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2157892A1 (enExample) | 1973-06-08 |
| US3784688A (en) | 1974-01-08 |
| FR2157892B1 (enExample) | 1976-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69711067T2 (de) | Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose | |
| DE60037277T2 (de) | Adenosinrezeptor-agonist oder antagonist enthaltende pharmazeutische zusammensetzungen | |
| DE60202278T2 (de) | Aktivierung natürlicher killerzellen durch adenosin-a3-rezeptoragonisten | |
| DE2036114B2 (de) | Wäßriges Tetramisolpräparat | |
| DE69323759T2 (de) | Verwendung von toremifene für die behandlung von sle | |
| DE69006046T2 (de) | Verwendung von Sialinsäure enthaltenden oder bindenden Stoffen zur Neutralisierung von bakteriellen Toxinen. | |
| DE68926746T2 (de) | Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel | |
| DE2802273C3 (de) | Verfahren zur Herstellung von Suppositorien aus Aminoglycid-Antibiotica | |
| DE69008853T2 (de) | Verwendung eines Derivates des 1,3,7-Trimethylxanthins zur Behandlung von Gedächtnisstörungen, intellektuellen Störungen im Alter, und bei der Alzheimerkrankheit. | |
| EP0575613A1 (de) | Arzneimittel mit antistress-, stressschutz- und nootroper wirkung | |
| DE2746974A1 (de) | Verwendung der pseudomonsaeure und ihrer salze und ester | |
| DE69226487T2 (de) | Verwendung von Furanonderivaten zur Vorbeugung oder Behandlung von Autoimmunkrankheiten | |
| DE2716402A1 (de) | 7-(2,3-dihydroxypropyl)-1,3-di-n- propylxanthin, verfahren zu seiner herstellung und diese verbindung enthaltende arzneimittel | |
| DE1793646A1 (de) | Glyoxaldithiosemicarbazone | |
| DE60211495T2 (de) | Xanthin-glycol-derivate zur behandlung des reizdarmsyndroms | |
| DE69907387T2 (de) | Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis. | |
| DE2251379A1 (de) | Angstunterdrueckende arzneipraeparate | |
| DE60220799T2 (de) | Hypoglykämisches mittel | |
| DE2719608A1 (de) | Benzodiazepinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| EP0331871A2 (de) | Antipsychotisch wirksames Imidazobenzodiazepin | |
| DE69221926T2 (de) | Synergische Mischung zur Behandlung von Angstzuständen | |
| DE2312134C2 (de) | Anthelmintikum | |
| DE602004009068T2 (de) | Glycosaminoglykane zur behandlung emotionaler störungen | |
| EP0259617A2 (de) | Verfahren und Präparat zur Inaktivierung von Viren | |
| EP0152860B1 (de) | Verwendung von Cephemverbindungen zur Herstellung eines Arzneimittels für die Modulation des Immunsystems |